Tabersonine

3 Cited Publications
Revisión del cliente

Based on 3 publication(s) in Google Scholar

Tabersonine is a selective, orally active NLRP3 inhibitor. Tabersonine directly binds to the NACHT domain of NLRP3, inhibiting its ATPase activity and oligomerization, thereby blocking ASC spot formation and caspase-1 activation, and reducing the release of pro-inflammatory cytokines such as IL-1β. Tabersonine also inhibits K63-linked ubiquitination of TRAF6, blocking NF-κB, PI3K/Akt, and p38 MAPK signaling pathways. Tabersonine can inhibit inflammatory responses, induce apoptosis of liver cancer cells through mitochondrial pathways and death receptor pathways, reduce mitochondrial membrane potential, promote cytochrome c release, and activate caspase proteins. Tabersonine is mainly used in the study of NLRP3-driven inflammatory diseases (such as acute lung injury, sepsis, peritonitis) and tumors such as liver cancer.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza : 98.02%
  • No. CAS: 4429-63-4
  • Fòrmula: C21H24N2O2
  • Peso molecular:336.43
  • Almacenamiento:

    4°C, protect from light

    * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

  • Actividad biológica
  • Chemical Information
  • Solvente y solubilidad
  • Protocolo
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00